AnaptysBio director acquires 1,300 RSU shares

ANAB director John A. Orwin had 1,300 RSUs settle into common stock at no cost, increasing his direct holdings to 17,995 shares.

Available on EDGAR 09/17/2026 - 04:06 PM EDT Accepted by SEC EDGAR 09/17/2026 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ANAPTYSBIO, INC (ANAB) director John A. Orwin reported the settlement of 1,300 Restricted Stock Units (RSUs) into 1,300 shares of Common Stock on September 15, 2026. Each RSU converted into one share for no cash consideration, bringing his directly held Common Stock position to 17,995 shares. The RSUs vest in three equal annual installments on September 15, 2024, 2025 and 2026, subject to continued service.

Insider Trade Summary

1,300 shares exercised/converted

Exercise 2 txns

Insider Orwin John A

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit F1, F2	1,300	$0.00	$0.00
Exercise	Common Stock F1	1,300	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock — 17,995 shares (Direct)

Holdings Before and After: Restricted Stock Unit, 1,300 to 0 contracts (Direct); Common Stock, 16,695 to 17,995 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
2. F2. The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date.

Key Figures

RSUs settled into Common Stock: 1,300 shares Common Stock acquired from RSU settlement: 1,300 shares Holdings after transaction: 17,995 shares +1 more

4 metrics

RSUs settled into Common Stock 1,300 shares Restricted Stock Units converted to Common Stock on September 15, 2026

Common Stock acquired from RSU settlement 1,300 shares Shares received upon RSU settlement, for no cash consideration

Holdings after transaction 17,995 shares Directly held ANAB Common Stock by John A. Orwin after September 15, 2026 transaction

RSU vesting schedule 3 equal installments RSUs vest one-third on each of September 15, 2024, 2025 and 2026

Key Terms

Restricted Stock Unit, contingent right, vesting date

3 terms

Restricted Stock Unit financial

"Each restricted stock award ("RSU") represents a contingent right to receive 1 share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

contingent right financial

"represents a contingent right to receive 1 share of the Issuer's Common Stock"

vesting date financial

"subject to the provision of services to the Company on each vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANAB director John A. Orwin report?

He reported the settlement of 1,300 Restricted Stock Units into 1,300 shares of ANAB Common Stock on September 15, 2026, with no cash consideration, as part of his equity compensation.

How many ANAB shares does John A. Orwin hold after this Form 4 transaction?

Following the September 15, 2026 transaction, John A. Orwin directly holds 17,995 shares of ANAPTYSBIO, INC Common Stock, as reported in the Form 4.

What are the terms of the RSUs reported by ANAB for John A. Orwin?

Each RSU represents a contingent right to receive one share of ANAB Common Stock for no consideration. The award vests in three equal installments on September 15, 2024, 2025 and 2026, subject to Orwin providing services on each vesting date.

Did John A. Orwin buy or sell ANAB shares for cash in this Form 4?

No. The Form 4 reports an exercise/conversion of RSUs into 1,300 shares of Common Stock for no cash consideration. It does not report an open-market purchase or sale for cash.

Was the ANAB insider transaction under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not checked, and no footnote describes a trading plan. The transaction is reported as an equity award vesting and settlement, not as a trade under a Rule 10b5-1 plan.

How do the ANAB RSUs for John A. Orwin vest over time?

The RSUs vest as to one-third of the total shares on September 15, 2024, one-third on September 15, 2025, and one-third on September 15, 2026, subject to continued service to the company on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Orwin John A

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		M		1,300	A	$0(1)	17,995	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	09/15/2026		M			1,300	(2)	(2)	Common Stock	1,300	$0	0	D

Explanation of Responses:

1. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date.

	/s/ Christopher Murphy, Attorney-in-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)